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In Brief
Mazor et al. show that spatial and
temporal patterns of DNA methylation
and somatic mutations during the
progression of low-grade gliomas to
high-grade tumors produce remarkably
similar evolutionary histories and both
converge to deregulate the cell cycle.
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http://dx.doi.org/10.1016/j.ccell.2015.07.012SUMMARYThe evolutionary history of tumor cell populations can be reconstructed from patterns of genetic alter-
ations. In contrast to stable genetic events, epigenetic states are reversible and sensitive to the microen-
vironment, prompting the question whether epigenetic information can similarly be used to discover tumor
phylogeny. We examined the spatial and temporal dynamics of DNA methylation in a cohort of low-grade
gliomas and their patient-matched recurrences. Genes transcriptionally upregulated through promoter
hypomethylation during malignant progression to high-grade glioblastoma were enriched in cell cycle func-
tion, evolving in parallel with genetic alterations that deregulate the G1/S cell cycle checkpoint. Moreover,
phyloepigenetic relationships robustly recapitulated phylogenetic patterns inferred from somatic muta-
tions. These findings highlight widespread co-dependency of genetic and epigenetic events throughout
brain tumor evolution.Significance
Deciphering the evolutionary history of a tumor illuminates the sequence of events that occurred in tumorigenesis prior to
diagnosis. The earliest events may provide ideal targets for precision therapeutic approaches because these alterations are
present in nearly all cells of a tumor. Here, we show that spatial and temporal patterns of either reversible DNAmethylation or
irreversible somatic mutations produce remarkably similar evolutionary histories. Phenotypically, mutations and promoter
region DNA hypomethylation converge to deregulate the cell cycle as indolent low-grade tumors progress to high-grade
malignancies. This study suggests strong interdependency of genetic and epigenetic alterations in these human brain
tumors.
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INTRODUCTION
Cancers develop through a process of clonal evolution in
which ongoing genetic and epigenetic diversification allows for
repeated cycles of subclonal selection and expansion (Greaves
and Maley, 2012; Nowell, 1976). As a result, human tumors
can display substantial intratumoral heterogeneity, including
discordant genetic alterations between initial tumors and their
associated local recurrences or distant metastases (Gerlinger
et al., 2012; Okosun et al., 2014; Wu et al., 2012; Yachida
et al., 2010). While genomic profiling of spatially or temporally
separated tumor samples can be used to reconstruct the evolu-
tionary history and underlying clonal architectures of individual
tumors (Gerlinger et al., 2014), this view is incomplete without
a parallel analysis of the heterogeneity and evolution of the
epigenome, an approach only rarely attempted (Brocks et al.,
2014; Oakes et al., 2014).
In low-grade glioma, the course of tumor evolution is partic-
ularly clinically significant. World Health Organization (WHO)
grade II gliomas (low-grade gliomas) are diffuse, infiltrative tu-
mors that frequently recur and may unpredictably undergo ma-
lignant progression to a higher grade with a worse prognosis
(Sanai et al., 2011). Recurrences that progress to highly malig-
nant WHO grade IV glioblastoma (GBM) acquire genetic alter-
ations in the RB and AKT-mTOR pathways (Cancer Genome
Atlas Research Network, 2008; Johnson et al., 2014; Louis,
2006). In fact, adjuvant treatment with alkylating chemothera-
peutics such as temozolomide (TMZ) can induce hypermutation
that emerges in recurrent tumors (Hunter et al., 2006), and we
recently linked treatment-associated driver mutations in these
two pathways to malignant progression of grade II glioma to
GBM (Johnson et al., 2014). It remains unknown, however,
how epigenetic alterations contribute to the different courses
of evolution of low-grade gliomas and how or if they relate to
concurrent mutational evolution.
The critical role that epigenetic alterations play in the develop-
ment and therapeutic response of gliomas is increasingly being
appreciated (Fouse andCostello, 2009). Epigenetic mechanisms
can alter gene expression and affect tumor suppressors and on-
cogenes in gliomas (Baeza et al., 2003; Costello et al., 1996; Kim
et al., 2006; Nagarajan et al., 2014; Nakamura et al., 2001;
Wiencke et al., 2007). Somatic mutation in IDH1 or IDH2 may
be the first genetic driver in the development of many low-grade
gliomas (Johnson et al., 2014; Lai et al., 2011; Watanabe et al.,
2009). Genetic mutations in IDH genes induce a pattern of early
epigenetic alterations known as the glioma CpG island methyl-
ator phenotype (G-CIMP) characterized by extensive remodeling
of the DNA methylome (Hill et al., 2014; Noushmehr et al., 2010;
Toyota et al., 1999; Turcan et al., 2012). The inactivation of other
genes mutated in low-grade gliomas, such as ATRX (Jiao et al.,
2012) and SMARCA4 (Johnson et al., 2014), is known to induce
specific DNA methylation changes as well (Banine et al., 2005;
Gibbons et al., 2000). Of clinical importance is DNA hypermethy-
lation of the MGMT promoter, which is associated with loss of
SP1 binding, closed chromatin, and transcriptional silencing in
GBM cells (Costello et al., 1994a, 1994b), and increased survival
in GBMpatients treated with TMZ (Hegi et al., 2005).Whether the
DNA methylation status at this locus predicts the same survival
benefit in patients with low-grade glioma is unclear (Everhard308 Cancer Cell 28, 307–317, September 14, 2015 ª2015 Elsevier Inet al., 2006; Kesari et al., 2009; Taal et al., 2011; van Thuijl
et al., 2015;Wick et al., 2013). Although there has been extensive
characterization of tumor methylomes using a single sampling
per tumor, little is known about intratumoral heterogeneity at
the epigenetic level or of temporal evolution of the low-grade
glioma methylome and its relationship to the genome. An inte-
grated model of the genomic and epigenomic evolutionary tra-
jectory of initially low-grade gliomas may suggest strategies for
delaying or treating recurrent disease, identify biomarkers for
predicting the clinical course of a low-grade glioma, and shed
light on dynamic relationships between the genome and epige-
nome in other cancer types.
RESULTS
We profiled the DNA methylomes of 19 clinically annotated
initial grade II gliomas and their patient-matched recurrences
(Table S1) using the Illumina HumanMethylation450 bead array
(Illumina 450K) (Figure S1A). We also performed transcriptome
sequencing on the initial and recurrent tumors of 13 patients
(Table S2). All gliomas profiled here are IDH1 mutant (Johnson
et al., 2014; van Thuijl et al., 2015) and are therefore expected
to possess the characteristic methylation patterns associated
with G-CIMP (Lu et al., 2012; Noushmehr et al., 2010; Turcan
et al., 2012). From these methylation array data, we confirmed
that G-CIMP was present in all initial tumors and always main-
tained at recurrence (Figure S1B), highlighting that these epige-
netic changes arise very early and are potentially tumor-initiating.
Patterns of DNA Methylation Are Patient-Specific and
Evolve in a Manner Specific to the Grade of Recurrence
To determine the extent to which these tumors had alteredmeth-
ylomes beyond the ubiquitous G-CIMPmethylation patterns, we
identified the most variable CpG sites across all initial and recur-
rent gliomas and performed unsupervised hierarchical clus-
tering. Initial and recurrent tumors from the same individual clus-
tered together (Figure S1C). This result reflects patient-specific
methylation patterns, consistent with a previous report on glioma
(Laffaire et al., 2011), and may be indicative of normal inter-indi-
vidual epigenetic variation, patient-specific aberrant methylation
from early stages of gliomagenesis, or both. Within the clus-
tering, six of the seven patients who recurred with GBM formed
a distinct subgroup, suggesting there may be a shared methyl-
ation pattern associated with malignant progression to GBM
relative to a lower grade of recurrence. To further evaluate this
pattern, we performed unsupervised clustering with progres-
sively more lenient selections of variable CpG sites to discover
additional global DNA methylation patterns. At intermediate
cut-offs, a gradual switch in clustering patterns was evident (Fig-
ure S1D). At the most lenient cutoff, the methylation patterns
separated GBM recurrences, as well as two initial tumors that
recurred as GBM, from the grade II and III gliomas (Figure 1A).
This further supports a GBM recurrence-specific methylation
pattern and suggests extensive evolution of the methylome
during malignant progression to GBM (Figure S1E). This unique
pattern of epigenome evolution was prominent across GBM
recurrences that arose in the absence of adjuvant therapy as
well as in GBMs that arose in a treatment-associated manner,
adding to our previous genetic findings that spontaneous andc.
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Figure 1. Evolutionary Dynamics of the Methylome and Transcrip-
tome in Initial and Recurrent Glioma Pairs
(A) Unsupervised hierarchical clustering of the top 50% most variable CpG
sites. Annotations of sample type, grade of recurrence, and patient identifi-
cation numbers are provided. The lines beneath the patient identification
numbers connect initial and recurrent tumors from the same patient that are
not adjacent to each other.
(B) The average methylation change from initial low-grade tumor to recurrence
at each CpG site measured in patients that do not (left) or do (right) undergo
malignant progression to GBM (grade IV). Colored dots represent CpG
sites that show significant hypomethylation (orange dots, total count
provided) or hypermethylation (green dots, total count provided) at recurrence
(p valueadjust < 0.05 and jDbj > 0.2).
(C) Average gene-level expression changes from initial to recurrence in
patients that do not (left) or do (right) undergo malignant progression to GBM.
Significantly differentially expressed genes are highlighted in green (down-
regulated at recurrence, total count provided) and orange (upregulated at
recurrence, total count provided) (p < 0.05 and jDlog2FPKMj > 1).
See also Figure S1 and Tables S1 and S2.treatment-associated progression to GBM have convergent ge-
netic alterations (Johnson et al., 2014). Interestingly, clustering of
the transcriptome segregated some of the grade III recurrences
with GBM samples (Figures S1F and S1G), indicating transcrip-
tional changes are complementary to, but not exclusively over-Canlapping with, changes in the DNA methylome during malignant
progression. Thus, integrating themethylome and transcriptome
may provide important insight into the functional epigenetic
events that underlie malignant progression to GBM.
Identification of CpGs that LoseMethylation Specifically
during Malignant Progression to GBM
We next examined changes in the methylome and transcriptome
to determine whether there is a signature of methylation or
expression changes associated with recurrence. We calculated
the change in methylation (b value, methylated fraction at a CpG
site) from initial to recurrent tumor at each CpG site in each pa-
tient, and then identified CpG sites with consistent methylation
changes upon recurrence across all patients. This powerful
intra-patient approach controls for differences in DNA methyl-
ation that are age-related or reflect germline genetic effects,
which confound inter-patient comparisons. DNA methylation
differences between normal brain and glioma may be aberrant
events in the tumor or may reflect differences between the
normal brain tissue sample and the methylation patterns of the
tumor’s cell of origin (Sproul et al., 2012; Witte et al., 2014). In
contrast, the differences we report between initial and recurrent
tumors are more likely to be aberrant changes attributable to
tumor progression rather than cell of origin. We also applied
an equivalent model to the transcriptome sequencing data and
identified genes that commonly increase or decrease in expres-
sion from initial to recurrent glioma (Figure S1H). The separation
by grade in the methylation clustering suggested that a specific
pattern of DNA methylation changes may underlie malignant
progression to GBM. To discover this pattern in detail, we strat-
ified patients by grade of recurrence. There were few common
methylation changes evident in tumors that recurred at grade II
or III, whereas a strong pattern of hypomethylation was associ-
ated with malignant progression to GBM (Figures 1B, 1C, and
S1I). Patients with tumors that recurred at grade II or III were
combined into a single group for further analysis.
To determine which methylation changes were specific to
recurrence as GBM, we compared the change in methylation
from initial to recurrence in patients who recurred asGBMversus
those that recurred at grades II or III. We identified 1,953 CpG
sites that were hypomethylated specifically upon recurrence as
GBM (Figure 2A and Table S3). Given the G-CIMP-associated
hypermethylation in these tumors, we first set out to determine
if the hypomethylation in GBM recurrences affected G-CIMP
genes. Noushmehr et al. (2010) identified 50 genes that were
hypermethylated and downregulated in a G-CIMP specific
manner. Only two of those genes (ACSS3 and RAB36) showed
GBM-specific hypomethylation, but in neither case did the genes
show concurrent increased expression. Further examination of
these sites of decreasing methylation revealed a surprising
enrichment for CpG sites that undergo age-related increased
methylation in a comparison of normal fetal and adult brain
(odds ratio 4.64, p < 0.0001, permutation test; see Supplemental
Experimental Procedures). This is contrary to the typical pattern
in cancer in which CpG sites that are hypermethylated during
aging are also hypermethylated in cancer (Issa et al., 1994;
Toyota et al., 1999). To further investigate whether the methyl-
ation changes alter gene regulation, we integrated active regu-
latory regions defined from histone H3K4me3, H3K4me1, andcer Cell 28, 307–317, September 14, 2015 ª2015 Elsevier Inc. 309
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Figure 2. Cell Cycle Genes Are Hypomethylated and Overexpressed Specifically upon Recurrence as GBM, Coordinately with an Increase in
Actively Cycling Cells
(A) Left: a scatterplot of differences between GBM and non-GBM recurrent tumors in methylation changes from initial grade II to recurrent gliomas. Right: an
equivalent representation of differences in expression changes between GBM and non-GBM recurrent tumors. Colored points indicate significant differences.
Purple triangles highlight genes that become hypomethylated at promoter CpGs (left) and overexpressed (right) during malignant progression to GBM.
(B)Barplot of the top results of ageneontologyanalysisof genes thatarebothsignificantly hypomethylatedandoverexpressedspecifically upon recurrenceasGBM.
(C) Representative staining for Ki-67 in a patient that recurred at grade III (left) and a patient that recurred at grade IV (right). Bars represent 100 mm.
(D) Boxplot representing the Ki-67 labeling index of tumors in the cohort (n = 16 patients), subdivided by grade of recurrence (p = 0.026, two-sidedWilcoxon rank
sum test between GBM recurrences and recurrences at grades II or III). The box encompasses data points between the first and third quartiles, with a horizontal
line indicating the median value. Whiskers extend to 1.53 interquartile range, and any data points beyond that range are shown as individual dots.
(E) Whole-genome shotgun bisulfite sequencing data (WGBS) of Patient01 across an intragenic CpG island in the TP73 locus. From top to bottom, tracks
represent a differentially methylated region (DMR) reported in primary GBM (Nagarajan et al., 2014); CpG island; TP73 full-length and truncated transcripts;
change in methylation level from initial to recurrent tumor by WGBS; statistical significance of the WGBS methylation changes, where positive values indicate
hypermethylation at recurrence and negative values indicate hypomethylation; methylation levels from Illumina 450K array in Patient01 at the seven CpG sites
assayed on the array. Box plots present the methylation change in all patients in the cohort across the same seven CpG sites. Boxplots are drawn as in (D).
See also Figure S2 and Tables S2, S3, and S4.H3K27ac chromatin immunoprecipitation sequencing in adult
normal brain and primary GBM tissue (Figure S2A and Table
S2) and found that sites of GBM-specific DNA hypomethylation
were enriched for candidate active enhancers (odds ratio
1.68, p < 0.0001, permutation test). These hypomethylated loci
thus may have gene regulatory effects. To enrich for functional
methylation changes and exclude passenger events, we next
integrated our transcriptome sequencing data with the DNA
methylation analysis.310 Cancer Cell 28, 307–317, September 14, 2015 ª2015 Elsevier InCell Cycle Genes Are Specifically Hypomethylated upon
Malignant Progression
We applied an analysis similar to that of the methylation data
and identified 528 genes with GBM-specific overexpression
(Figure 2A). Of these, 39 genes showed GBM-specific hypome-
thylation of at least one CpG site within their promoter regions
(Figures S2B and S2C; Table S3). Among genes with GBM-spe-
cific promoter hypermethylation, onlyNTSR2 showed consistent
transcriptional downregulation. We additionally identified fourc.
genes with consistent downregulation and gene body hypome-
thylation (Table S3). Strikingly, the set of 39 hypomethylated
and overexpressed genes was significantly enriched for cell
cycle genes (Figure 2B and Table S4). Ki-67 is a marker of
actively proliferating cells, and staining in initial and recurrent
tumors confirmed that a statistically significantly higher fraction
of cells (p = 0.026, two-sided Wilcoxon rank sum test) were
actively proliferating among the GBM recurrences (Figures 2C
and 2D). Increased proliferation is a hallmark of GBM. These
results thus highlight an epigenetic mechanism that may
contribute to increased proliferation, concurrent with genetic
alterations in key members of the RB pathway (Johnson et al.,
2014) that abrogate the G1/S cell cycle checkpoint.
Among the epigenetically modified cell cycle genes, we noted
that the hypomethylation in TP73 was at an internal gene body
promoter. Indeed, TP73 possesses a gene body CpG island
(CGI) that we identified recently as recurrently hypomethylated
in primary GBM (Nagarajan et al., 2014). The gene body CGI
spans the transcription start site of a truncated, oncogenic
form of TP73 (DNp73), which is correspondingly expressed in
primary GBM. Similarly, increased expression (Figure S2D) and
hypomethylation of DNp73 was observed only in GBM recur-
rences. Due to the limited resolution of the Illumina 450K array,
we identified only one significantly hypomethylated CpG site in
this gene body CGI specifically upon recurrence as GBM,
although several nearby CpG sites showed a similar trend. To
gain greater resolution across the full CGI and other regions
genome-wide, we examined our whole-genome shotgun bisul-
fite sequencing (WGBS) data on the initial and recurrent tumors
of Patient01 (Figure 2E and Table S2). These data show that the
pattern of hypomethylation indeed extends across the local
genomic region. Among other hypomethylated and overex-
pressed genes, significant probes from array-based data were
similarly indicative of a local effect including multiple CpG sites
(Figures S2E and S2F), consistent with previous literature
showing that the methylation levels of CpG sites within 1kb are
highly correlated (Eckhardt et al., 2006).
The functional effect of DNA hypomethylation of cell cycle
genes specifically upon recurrence as GBM parallels the known
GBM-specific genetic events that inactivate the G1/S cell cycle
checkpoint (Cancer Genome Atlas Research Network, 2008;
Johnson et al., 2014; Louis, 2006). These convergent genetic
and epigenetic signals, in addition to thewell-characterized func-
tional relationships between genetic and epigenetic aberrations
(Banine et al., 2005; Gibbons et al., 2000; Kerkel et al., 2008; Lu
et al., 2012; Turcan et al., 2012), prompted us to explore evolu-
tionary relationshipsamongdifferent tumorcell populationswithin
a tumor, as has been previously done with genetic data, and then
compare the relationships inferred fromDNAmethylation to those
inferred from somatic mutation in the same samples.
Reconstruction of Tumor Evolution from Intratumoral
and Longitudinal DNA Methylation Patterns
We first examined the evolutionary relationships of tumor sam-
ples that were previously genetically characterized (Johnson
et al., 2014). We performed methylation profiling of seven
spatially distinct pieces of tumor tissue from Patient17, three
from the initial tumor and four from the recurrent tumor, and built
a phyloepigenetic tree (Figure 3A, left; Table S3). The phyloepi-Cangenetic tree presented an intriguing model with early divergence
between the initial and recurrent tumors, and more subtle
divergences among the samples within each time point (initial
A versus initial B/C; recurrence A/C versus recurrence B/D).
We then used exome sequencing data of these same spatially
distinct tumor samples to independently construct a phyloge-
netic tree (Figure 3A, right, and Table S5) (Johnson et al.,
2014). The genetically defined relationships among tumor
cell clones were consistent with those determined from DNA
methylation data. We quantified this similarity as the correlation
between the distance matrices that were used to build the phy-
loepigenetic and phylogenetic trees (Spearman’s rho = 0.90).
To identify the CpG sites underlying each branch point in the
phyloepigenetic tree, we applied singular value decomposition
to the methylation data from each patient to weigh the influence
of individual CpG sites on separating particular subsets of sam-
ples (Figure S3A). For Patient17, the first singular vector (SV1),
which accounts for the most methylation variability, mimicked
the first major branch point of the phyloepigenetic tree (Fig-
ure 3B). We then selected the most influential CpGs for each
singular vector and inferred that these underlie a particular
branch point. The most highly weighted CpG sites within SV1
from Patient17 clearly showed differential methylation between
the initial and recurrent tumor samples (Figure 3C). We examined
the potential implications of these methylation changes by
focusing on those affecting active promoters and enhancers in
normal brain and primary GBM tissue and performed a gene
ontology enrichment analysis. For Patient17, the CpG sites that
underlie the first major branch point were enriched for a variety
of developmental, biosynthetic and metabolic processes, indi-
cating that methylation changes during tumor progression may
influence cellular metabolic states, in parallel with the genetic
events disrupting cell cycle that separate these two main
branches on the phylogenetic tree (Table S4).
We then looked specifically at the evolutionary relationships of
tumor samples from patients who underwent chemotherapy-
associated malignant progression (Johnson et al., 2014; van
Thuijl et al., 2015). We performed methylation profiling of four
spatially distinct pieces of the initial tumor and three pieces of
recurrent tumor from Patient01 and inferred a phyloepigenetic
tree (Figure 3D, left; Figure S3B and Table S3). Whereas the
four pieces of the initial tumor clustered together, the recurrent
tumor consisted of two distinct populations. Recurrence B was
relatively closely related to the initial tumor, while a long branch
separated it from recurrences A and C, indicating significant
evolutionary distance. A phylogenetic tree from these same tu-
mor pieces (Figure 3D, right; Tables S2 and S5) similarly demon-
strates the large evolutionary distance between recurrence B
and recurrences A and C (Spearman’s rho = 0.83). In the phylo-
genetic tree, this longest branch corresponds to the develop-
ment of a hypermutated population in the recurrent tumor.
Intriguingly, this same branch is the longest in the phyloepige-
netic tree, indicating that the hypermutated cells also have the
greatest methylation change. Similarly, in Patient18, the phyloe-
pigenetic tree identified three epigenetically similar pieces of the
initial tumor, a piece of the initial tumor that branched off at an
earlier evolutionary time point, and a recurrence that diverged
even earlier—relationships that are accurately recapitulated in
the phylogenetic tree (Spearman’s rho = 0.90) (Figures 3E andcer Cell 28, 307–317, September 14, 2015 ª2015 Elsevier Inc. 311
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Figure 3. The Spatial and Temporal Patterns of Tumor Evolution Observed from DNA Methylation Dynamics and Somatic Mutations Yield
Similar Evolutionary Histories
(A) A phyloepigenetic tree constructed from seven samples from Patient17 (left) and a phylogenetic tree derived from somatic mutations from exome sequencing
of the same DNA samples (right) (Spearman’s rho = 0.90). Tumor grade is provided in parentheses after each sample name.
(B) Singular value decomposition biplot shows the probes involved in separating tumor samples. Each probe used to build the phyloepigenetic tree in (A) is plotted
(gray dots). The most highly weighted probes are highlighted (triangles).
(C) A heatmap of the beta values at the 220 probes most highly weighted by SV1.
(D) A phyloepigenetic tree (left) and a phylogenetic tree (right) were constructed to infer the evolutionary relationships within and between the initial and recurrent
tumors of Patient01 (Spearman’s rho = 0.83). Tumor grade is provided in parentheses after each sample name.
(E–G) Phyloepigenetic (top) and phylogenetic trees (bottom) for Patient18 (E, Spearman’s rho = 0.90), Patient90 (F, Spearman’s rho = 0.56), and Patient49
(G, Spearman’s rho = 0.64). Tumor grade is provided in parentheses after each sample name.
See also Figure S3 and Tables S3, S4, S5, and S6.
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Figure 4. Phyloepigenetic Trees Coupled with Phylogenetic Trees from a Patient with Low-Grade Glioma with Three Recurrences Reveal an
Enhanced Understanding of Evolutionary Relationships
Phyloepigenetic (left) and phylogenetic (right) trees of Patient04 present evolutionary relations across four surgical time points (Spearman’s rho = 0.78). Tumor
grade is provided in parentheses after each sample name.
See also Figure S4 and Tables S3, S5, and S6.S3C; Tables S3 and S5). Thus, even in extreme evolutionary
events such as chemotherapy-associated hypermutation, both
DNA methylation changes and mutational landscapes encode
similar tumor evolutionary relationships. In these two cases
with TMZ-associated hypermutation (Figures 3D and 3E), the
longest branch length in both the phyloepigenetic and phyloge-
netic trees is the hypermutated recurrence. These results sug-
gest a potentially quantitative relationship between the number
of mutations and epimutations in each tumor cell clone.
To determine if the strong correlations between phylogenetic
and phyloepigenetic trees depend on the large-scale hypo-
methylation during malignant progression to GBM, we next
compared theevolutionary relationships only in lower grade initial
and recurrent tumors. Six pieces of tissue from the initial tumor
and two pieces of tissue from the grade II recurrence from
Patient90 were subjected to DNA methylation profiling. Con-
struction of a phyloepigenetic tree revealed threedistinct clusters
of samples, with the initial tumor separating into two populations,
and the recurrence forming a third (Figure 3F, top; FigureS3Dand
Table S3). We then performed exome sequencing of these same
pieces of tissue to identify somatic mutations and constructed a
phylogenetic tree (Figure 3F, bottom; Tables S2 and S5). This
phylogenetic treemirrored the evolutionary relationships defined
from DNA methylation (Spearman’s rho = 0.56). We further pur-
sued this question with Patient49 who underwent a single resec-
tion for an initial tumor fromwhichweprofiled six spatially distinct
pieces. Construction of a phyloepigenetic tree revealed that the
six pieces separate into two groups, in agreement with the phylo-
genetic tree derived from exome sequencing of the same pieces
of tissue (Spearman’s rho=0.64) (Figures 3GandS3E; TablesS2,
S3, and S5). Thus, even in the absence of malignant progression
to GBM, DNA methylation changes among tumor cell clones
yielded a very similar evolutionary trajectory as was inferred
from somatic mutations.
Enhanced Model of Tumor Evolution Derived from
Variation between Phyloepigenetic and Phylogenetic
Trees
To further address phyloepigenetic relationships over time, we
examined tumor samples from Patient04, who underwent fourCansequential surgical resections over 5 years. We profiled six
spatially distinct pieces of tumor from the initial surgery, and
one from each of the three subsequent surgeries for tumor recur-
rence. The phyloepigenetic tree reveals two distinct populations
within the initial tumor and an evolutionary trajectory shared
among the three recurrences, with a relatively closer relationship
between recurrences 2 and 3 (Figure 4, left; Figure S4 and Table
S3). The phylogenetic tree again reveals many similar clonal re-
lationships, but also reveals differences that may be informative
(Figure 4, right; Tables S2 and S5) (Spearman’s rho = 0.78).
Based on somatic mutations, the first recurrence shares evolu-
tionary history with the initial tumor, while the second recurrence
diverges earlier in the evolution of the tumor and therefore inde-
pendently progressed to grade III (Johnson et al., 2014). Despite
divergent genetic paths, methylation patterns are shared among
the first recurrence and the second and third recurrences. This
raises the possibility that the last common ancestor of the first
and second recurrences was primed for progression with a set
of DNAmethylation changes required for progression to a higher
grade. This case illustrates how differences in genetic and epige-
netic phylogenies may bring to light an enhanced understanding
of the evolution of a tumor.
Gene-Level Genetic and Epigenetic Convergence
The common evolutionary histories defined from mutations and
DNA methylation led us to examine if there was also conver-
gence at the level of individual genes. We identified a small
number of intra-patient single gene convergence events in which
some samples from a patient had a mutation, whereas other
samples that lack the mutation show differential methylation
at the same gene (Table S6; see Supplemental Experimental
Procedures). We also identified a small number of genes with
inter-patient convergence. These are genes that are mutated in
one patient but show methylation alteration in another patient
(Table S6; see Supplemental Experimental Procedures). How-
ever, the vast majority of mutations and methylation changes
occur in different sets of genes, consistent with our prior low-
resolution analysis of gliomas (Zardo et al., 2002). In contrast
to single genes, single pathways such as the cell cycle pathway
are commonly altered by multiple genetic (Johnson et al., 2014)cer Cell 28, 307–317, September 14, 2015 ª2015 Elsevier Inc. 313
Intratumoral
heterogeneity
genetic       epigenetic
IDH1     G-CIMP
TP53, ATRX
CNA
Altered intratumoral
heterogeneity due 
to surgical resection
Surgical resection
Surgical resection
RB and Akt-mTOR pathway aberrations
DNA hypomethylation of cell cycle genes
Malignant progression to grade IV Recurrence at grades II, III
Sp
on
ta
ne
ou
s
M
M
R,
 
M
GM
T
Tu
m
o
r 
in
iti
at
io
n
In
iti
al
 tu
m
or
R
es
id
ua
l d
ise
as
e
R
ec
ur
re
nt
 tu
m
or
Tr
e
a
tm
en
t
as
so
cia
te
d
Tr
ea
tm
en
t-
Figure 5. A Genomic and Epigenomic Co-dependency Model of
Clonal Evolution
Low-grade gliomas exhibit intratumoral heterogeneity at initial presentation,
with subclones that share the initiating genetic (IDH1 followed by TP53 and
ATRX and copy number alterations [CNA]) and epigenetic (IDH1-associated
glioma CpG island methylator phenotype [G-CIMP]) alterations, but further
develop distinct genetic and epigenetic characteristics. Following surgical
resection, the outgrowth from residual disease may be grade II or III, while still
continuing to evolve subclones with genetic and co-dependent epigenetic
features that are distinct from the initial tumor. In other patients, residual dis-
ease may undergo malignant progression to GBM, either spontaneously or
because of treatment-associated mutations, in either case acquiring genetic
defects in the RB and Akt-mTOR pathways and promoter hypomethylation
and activation of cell cycle genes. Treatment-associated progression to GBM
is uniquely associated with an increased epigenetic silencing of MGMT (van
Thuijl et al., 2015) and acquisition of genetic defects in mismatch repair genes.and epigenetic (Figure 2B) alterations within and across tumor
samples.DISCUSSION
DNA methylation patterns record a remarkable breadth of infor-
mation about cells, including their chronological age, develop-
mental history, and differentiation potential. Here, we show314 Cancer Cell 28, 307–317, September 14, 2015 ª2015 Elsevier Inthat despite epigenome plasticity, chemotherapy, and the ubiq-
uitous IDH1 mutation-driven G-CIMP pattern, patient-specific
tumor phyloepigenetic analyses replicated and extended tumor
phylogenetic analyses. From this striking result, we conclude
that the precise chronological order of epigenetic changes,
from initiating to late events, can be determined from intratu-
moral methylation patterns, thus surpassing prior binary catego-
rization of epigenetic events as early or late. While our study is
focused on methylation and somatic mutations in IDH1 mutant
gliomas, a study of prostate cancer and prostate cancer metas-
tasis showed a complementary unified model of evolution for
DNA methylation and copy number alterations (Brocks et al.,
2014). Thus, genomic-epigenomic co-dependency may be a
feature of multiple types of cancer, and may span somatic muta-
tions, copy number, and DNA methylation.
The importance of epigenetic variation within individual human
tumors is just beginning to be uncovered. Recent work in
chronic lymphocytic leukemia suggests that stochastic changes
in the methylome lead to increased heterogeneity, allowing for
selection of more malignant epi-phenotypes coupled with an
adverse clinical outcome (Landau et al., 2014). Somatic genetic
events, such as IDH1 mutations, have been directly linked to
alterations in the methylome (Noushmehr et al., 2010; Turcan
et al., 2012), whereas germline variants have been indirectly
associated with specific DNA methylation patterns (Heyn et al.,
2013; Kerkel et al., 2008; Shi et al., 2014). Consistent with
these theories, the widespread correlation between somatic
mutations and DNA methylation patterns suggests that in addi-
tion to IDH1 mutation and G-CIMP, other epigenetic patterns
might be directly or indirectly induced by mutations, or vice
versa. It will be of interest to determine the extent to which these
findings hold for IDH1-wild-type low-grade gliomas and their
recurrences.
We also discovered a convergence of genetic and epigenetic
changes driving aberrant cell cycle function (Figure 5). We previ-
ously found that recurrent tumors that underwent malignant pro-
gression to GBM acquired somatic mutations in the RB pathway
that inactivate the G1/S cell cycle checkpoint (Johnson et al.,
2014). Here we identified a pattern of functional DNA hypome-
thylation specific to recurrence as GBM that alters cell cycle
genes. This phenotypic convergence of genetic and epigenetic
mechanisms on the same pathway underscores the importance
of cell cycle deregulation on the process of malignant pro-
gression, while also raising questions about how these two
processes might be connected. Of note, we identify hypomethy-
lation at TP73 as a recurrent event. Transcription of TP73 is
upregulated by E2F1 (Rufini et al., 2011), a transcription factor
that itself activates cell cycle progression-related genes
following inactivation of the RB pathway (Chen et al., 2009),
which is deregulated by genetic mechanisms in these tumors.
Further work will be required to deconvolute these relationships.
By combining the information from somatic mutations, copy
number alteration and DNA methylation patterns, we derived
a comprehensive model of glioma evolution (Figure 5). Chrono-
logical ordering of IDH1, TP53, and ATRX mutations and copy
number alterations was derived from our previous tumor phylo-
genetic analyses (Johnson et al., 2014), other studies (Lai
et al., 2011; Watanabe et al., 2009), and additional data pre-
sented here. This model is derived from 32 patients with pairedc.
initial and recurrent samples and includes 70 DNA methyla-
tion profiles, 26 mRNA expression profiles and 130 exome
sequencing profiles. The model extends from the initiating ge-
netic and epigenetic lesions and captures clinically divergent
paths at recurrence, including an evolutionary path driven by
treatment.
These findings underscore the power of integrated genetic
and epigenetic analyses of tumors. Deregulated cell cycle con-
trol is among the essential phenotypes of cancer cells, and we
demonstrate that this deregulation is encoded in both the
genome and epigenome, raising the question of the extent to
which this reflects a functional interaction between genetics
and epigenetics. This finding also raises the possibility that other
critical molecular phenotypes, such as genomic instability,
angiogenesis, or invasion, may leave their imprint on DNA
methylation patterns during tumor evolution.
EXPERIMENTAL PROCEDURES
Sample Acquisition
Flash-frozen tissue was acquired from patients undergoing surgical resection
for glioma. Samples were obtained from the Neurosurgery Tissue Bank at the
University of California San Francisco (UCSF). Sample use was approved by
the Committee on Human Research at UCSF, and research was approved
by the Institutional Review Board at UCSF. Additional samples were obtained
from Erasmus Medical Center with the approval of the Medical Ethics
Committee at Erasmus Medical Center Rotterdam and the OncoNeuroTheque
tissue bank at Groupe Hospitalier Pitie´-Salpeˆtrie`re with the approval of the
Ethics Committee. All patients provided informed written consent. Genomic
DNA was extracted, and where tissue availability was sufficient and high-
quality RNA was obtained, strand-specific transcriptome sequencing was
performed. Complete details are provided in the Supplemental Experimental
Procedures.
DNA Methylation Analysis
Genomic DNA from 70 samples was bisulfite converted using the EZ
DNA Methylation Kit (Zymo Research) and processed on Infinium
HumanMethylation450 bead arrays (Illumina) according to the manufacturer’s
protocol. Probe-level signals for individual CpG sites were subject to both
background and global dye-bias correction (Triche et al., 2013). Probes
that map to regions with known germline polymorphisms, to multiple genomic
loci (Price et al., 2013), or to either sex chromosome were filtered out. Descrip-
tions of further analyses are provided in the Supplemental Experimental
Procedures.
Transcriptome Sequencing Analysis
Strand-specific transcriptome sequencing libraries were prepared as previ-
ously described (Johnson et al., 2014). All transcriptome sequencing data
from initial and recurrent tumor pairs were aligned with TopHat (v2.0.12)
(Trapnell et al., 2009) to the hg19 reference genome using a GENCODE V19
transcriptome-guided alignment. The aligned data were then processed
through custom quality-control scripts to remove unmapped, improperly
matched, multi-mapping, and chimeric reads, as well as accumulation in
non-assembled chromosomes. To estimate transcript abundance, aligned
data were processed with the cuffnorm and cuffquant commands from
the Cufflinks package (v2.2.1) (Trapnell et al., 2010). Further details on
process and statistical analysis are provided in the Supplemental Experimental
Procedures.
Exome Sequencing and Mutation Identification
Exome capture was performed using either Agilent or NimbleGen exome
capture kits on 48 samples, 22 of which were previously published
(Johnson et al., 2014; van Thuijl et al., 2015). All sequencing reported
here acquired paired-end reads from Illumina HiSeq instrumentation.
Exome alignment and mutation calling were performed as previouslyCandescribed (Johnson et al., 2014). To generate a list of only the highest
quality variants for phylogenetic tree construction, further filtering was
applied by excluding all SNVs that were not classified as ‘‘covered’’ by
MuTect in all samples for that patient, SNVs with any variant reads detected
in the patient-matched normal and all indels, unless validated by Sanger
sequencing.
Construction of Phylogenies
For the phylogeny analysis of both the genetic and epigenetic data, we used an
independent, but parallel, analysis of the methylation data and exome-seq
mutations. For the exome-seq data, we used binary mutation calls to build a
distance matrix for all samples from a patient using the Manhattan distance
metric, including a normal tissue sample for which all mutations were absent.
Similarly, for the methylation data, we used only the probes that had a beta
value difference of at least 0.4 between any of the samples from a patient to
build a Euclidean distance matrix. Using several other probe selection cut-
offs produced similar results. A normal brain sample (adult insula tissue from
a different individual) was not included in the probe selection, but was added
to the distance matrix calculation to serve as the tree root. To compare the dis-
tancematrices from themutation data and themethylation data, we calculated
the Spearman’s rho correlation. We then built the phylogeny trees using an or-
dinary least-squaresminimum evolution (Desper andGascuel, 2002) approach
from the ape R package (Paradis et al., 2004) using the distance matrices from
the genetic and epigenetic data independently.
Identifying Discriminative Methylation Probes by Singular Value
Decomposition
To identify the probes most responsible for a particular bifurcation on a
phyloepigenetic tree (similar to identifying mutations that differ between two
branches of a phylogenetic tree), we used singular value decomposition of
the methylation data matrix to calculate the left and right singular vectors that
form orthonormal bases of the subspaces spanned by the columns and rows
of the data matrix, respectively. Projecting the columns, corresponding to
samples, onto the two-dimensional subspace spanned by the first two left sin-
gular vectors (SV) reduces the data to the first two principal components that
maximally separate the samples in the probe space. These projections are
shownas arrows in Figure 3B,where the rowsof the first two left SVs are plotted
as scatter points representing probes. In this biplot, the probes that best sepa-
rate samples have large absolute values in the SV1 direction. Additional details
are provided in the Supplemental Experimental Procedures.
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